Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03624309
Recruitment Status : Not yet recruiting
First Posted : August 10, 2018
Last Update Posted : September 17, 2018
Sponsor:
Information provided by (Responsible Party):
Hunan Cancer Hospital

Brief Summary:
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit kinase. In the phase Ⅲ study, patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months. Therefore,we envisage using anlotinib plus docetaxel treat the EGFR wild-type advanced Non-small cell lung cancer patients who were failure in the treatment of chemotherapy with platinum containing drugs, to further improve the patient's PFS or OS.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: Anlotinib Plus Docetaxel Drug: Docetaxel Phase 2

Detailed Description:

This is a multicentre randomised controlled clinical trial conducted in China to compare the effectiveness and safety of Anlotinib Plus Docetaxel in patients of EGFR wild-type Advanced Non-squamous Non-small Cell Lung Cancer.

Eligible patients will be randomized to arm A and arm B:

Arm A: Patients on the anlotinib and docetaxel arm received 75mg/m2 docetaxel as intravenous infusion on day 1 of a 21-day cycle and 12mg anlotinib orally daily on day 1to 14 of a 21-day cycle.

Arm B: Patients on the docetaxel arm received 75mg/m2 docetaxel as intravenous infusion on day 1 of a 21-day cycle.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anlotinib Plus Docetaxel Versus Docetaxel for Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy : a Multicentre, Double-blind, Randomised Explorative Trial
Estimated Study Start Date : October 15, 2018
Estimated Primary Completion Date : October 1, 2019
Estimated Study Completion Date : October 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Anlotinib Plus Docetaxel
Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Drug: Anlotinib Plus Docetaxel
Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)

Active Comparator: Docetaxel
Docetaxel (75mg/m2 IV d1)
Drug: Docetaxel
Docetaxel (75mg/m2 IV d1)




Primary Outcome Measures :
  1. PFS [ Time Frame: each 42 days up to PD or death(up to 24 months) ]
    Progress free survival


Secondary Outcome Measures :
  1. OS [ Time Frame: From randomization until death (up to 24 months) ]
    Overall Survival

  2. ORR [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]
    Objective Response Rate

  3. DCR [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]
    Disease Control Rate

  4. Safety (Number of Participants with Adverse Events as a Measure of Safety and Tolerability) [ Time Frame: Until 21 day safety follow-up visit ]
    Number of Participants with Adverse Events as a Measure of Safety and Tolerability



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • signed and dated informed consent
  • diagnosed with advanced NSCLC (phase IIIB/IIIC/IV) through pathology, with measurable nidus(using RECIST 1.1)
  • have failed for platinum two drugs chemotherapy
  • EGFR wild type
  • ECOG PS:0-1,Expected Survival Time: Over 3 months
  • main organs function is normal
  • the woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 2 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 2 months after it

Exclusion Criteria:

  • Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)
  • have used docetaxel before
  • have used antiangiogenic drugs (except Bevacizumab)
  • have failed for two times or beyond of platinum two drugs chemotherapy(except adjunctive therapy,neoadjuvant therapy and concurrent chemoradiotherapy )
  • iconography (CT or MRI) shows that the tumor vessels have 5 mm or less, or Cardiovascular involvement by Central tumor ; Or obvious lung empty or necrotic tumor
  • patients with brain or central nervous system metastases, including leptomeningeal disease, or CT/MRI examination revealed brain or leptomeningeal disease) (28 days before the random treatment has been completed and the symptoms of patients with brain metastases from stable can into the group, but need to the cerebral MRI, CT or vein angiography confirmed as without symptoms of cerebral hemorrhage)
  • patients are participating in other clinical studies (other than non-interventional studies) less than 4 weeks from the end of a previous clinical study
  • other kinds of malignancies within 5 years or for now
  • have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included
  • abnormal coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT ULN > 1.5), with bleeding tendency or be treated with thrombolysis and anticoagulation
  • urine routines show urine protein≥ ++, or urine protein quantity≥ 1.0 g during 24 hours
  • uncontrollable hypertensive (systolic blood pressure or greater 150 mmHg or diastolic blood pressure or greater 90 mmHg, despite the best drug treatment)
  • the effects of surgery or trauma had been eliminated for less than 14 days before admission to the study group
  • patients with severe infections , and need to receive Systemic antibiotic treatment
  • significant cardiac disease as defined as: grade II or greater myocardial infarction, unstable arrhythmia(Including corrected QT interval (QTc )period between male or greater 450 ms, female or greater 470 ms); New York Heart Association (NYHA) grade II or greater heart dysfunction , or Echocardiography reveal left ventricular ejection fraction (LVEF)Less than 50%
  • patients with NCI-CTCAE grade II or greater peripheral neuropathy, except due to trauma
  • pleural effusion or ascites, resulting in respiratory syndrome (≥CTC AE level 2)
  • serious, non-healing wound, ulcer, or bone fracture
  • decompensated diabetes or high dose glucocorticoid treatment of other contraindication
  • has an obvious factor influencing oral drug absorption, such as unable to swallow, chronic diarrhea and intestinal obstruction, etc
  • has Clinically significant hemoptysis Within 3 months before Random (daily hemoptysis than 50 ml;Or significant clinical significance of bleeding symptoms or have definite bleeding tendency, such as gastrointestinal bleeding, bleeding ulcers, baseline period + + and above of fecal occult blood, or vasculitis, etc
  • has venous thromboembolism events Within 12 months before Random, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc
  • whole body antitumor treatment was planned in the first 4 weeks(except diphosphonate) or during this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy, Chinese medicine with antitumor effect. Field scale radiotherapy (EF-RT) within 4 weeks before grouping or limited field radiotherapy before grouping were carried out in 6 months ;
  • a known history of HIV testing positive or acquired immunodeficiency syndrome (AIDS)
  • untreated active hepatitis (hepatitis b: HBsAg positive and HBV DNA more than 1 x 103 copy /ml; Hepatitis c: HCV RNA is positive and liver function is abnormal); Combined with hepatitis b and hepatitis c infection
  • serious diseases that endanger patients' safety or affect patients' completion of research,according to the researchers' judgment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03624309


Contacts
Layout table for location contacts
Contact: LIN WU, professor 008613170419973 wulin-calf@vip.163.com

Sponsors and Collaborators
Hunan Cancer Hospital
Investigators
Layout table for investigator information
Principal Investigator: LIN WU, professor Hunan Cancer Hospital

Layout table for additonal information
Responsible Party: Hunan Cancer Hospital
ClinicalTrials.gov Identifier: NCT03624309     History of Changes
Other Study ID Numbers: ALTER-L018
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: September 17, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action